ReviewInternational journal of molecular medicine2026
Interpretation of the molecular mechanism and therapeutic potential of microRNA‑155 in cardiovascular and cerebrovascular diseases (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- MicroRNA-155 at the crossroads of inflammation and vascular dysfunction in essential hypertension.Molecular biology reports · 2026Review
- Hypoxia-preconditioned bone marrow mesenchymal stem cells alleviate acute liver failure in association with the VEGF/c-Met pathway.Molecular biology reports · 2026Article
- A multi-biomarker nomogram based on miR-155-5p and NETs predicting deep vein thrombosis risk stratification.Thrombosis journal · 2026Article
- Higher Expression of miR-155 and miR-103 in Patients with Gitelman Syndrome: Potential Implications for Angiotensin II-Induced Cardiovascular Remodeling in Hypertension.Kidney & blood pressure research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA‑155 (miR‑155), a highly conserved non‑coding RNA, serves a pivotal role in the initiation and progression of cardiovascular and cerebrovascular diseases (CCVDs) through the modulation of target gene expression. miR‑155 contributes to the pathogenesis of conditions such as atherosclerosis, myocardial infarction, heart failure, hypertension and stroke, with mechanisms involving the regulation of endothelial function, inflammatory responses, oxidative stress, apoptosis and fibrosis. These findings suggest its potential as a biomarker. The present review provides a comprehensive overview of the biogenesis, regulation and biological functions of miR‑155, highlights its molecular mechanisms in CCVD progression, and examines current advances in therapeutic strategies targeting miR‑155, offering insights into the pathological mechanisms and precision treatment approaches for CCVDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.